Tempus AI announced the development of xH, its first whole-genome sequencing (WGS) test. This assay marks Tempus’s initial foray into adopting WGS as a platform, aiming to support clinicians with the detection of all clinically-relevant variants and advance personalized therapy, specifically in hematological oncology.
Currently available for research use only (RUO), xH is expected to be clinically available within the next year. The test is also designed to support Tempus's biopharma collaborators by providing unique insights from whole-genome sequencing.
A pilot study of 135 patients demonstrated high sensitivity in detecting clinically-relevant genetic alterations across myeloid malignancies, with a concordance rate over 98.9% compared to traditional molecular methods. The study highlighted WGS's potential as a cost-effective, comprehensive tool that consolidates multiple tests into a single assay.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.